GMMG-CONCEPT trial: Isa-KRd for the treatment of high-risk newly diagnosed MM
We summarize key results from the phase II GMMG-CONCEPT trial investigating transplant-eligible and non-transplant-eligible patients with newly diagnosed high-risk multiple myeloma treated with isatuximab, carfilzomib, lenalidomide, and dexamethasone, followed by triplet maintenance.